Navigation Links
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
Date:11/12/2013

patient treated at Emory University Hospital and the second patient treated at University of Michigan Health System. The multicenter trial is designed to treat up to 15 ambulatory ALS patients in five different dosing cohorts. Patients in the first cohort received 10 injections of 200,000 cells per injection. In subsequent cohorts, the dose will increase in both number of injections and cells per injection, advancing up to a maximum of 40 injections and up to 400,000 cells per injection in the fifth cohort. The first 12 patients will receive injections in the cervical region of the spinal cord only, where the stem cells could help preserve breathing function. The final three patients will receive both cervical and lumbar injections.

Corporate News:

This quarter, Neuralstem increased its global IP portfolio to 49 issued and 59 pending patents. The company received issuance of Japan Patent # 5266297, and filed a new patent application in South Korea, 10-2013-7020263, both related to the company's existing stem cell technology. The company also filed a new U.S. patent application 61/844,165, which covers methods of treating cognitive defects with spinal cord neural stem cells.

In September, the company raised aggregate gross proceeds of $4,556,000 in a registered direct offering.

In September, President and CEO Richard Garr presented at the Stem Cells & Regenerative Medicine Congress. NSI-566/ALS Phase I patient, Ted Harada, also spoke about his experience with ALS and treatments at the congress.

Subsequent News:

In October, University of Michigan Health System, the second center for the NSI-566/ALS Phase II dose escalation trial, treated its second patient. With one patient already treated at Emory University Hospital, this represented the completion of the first of the trial's five cohorts in less than a month's time.

In October, Dr. Eva Feldman, MD, PhD, gave an update on the NSI-566/ALS trial at the annual Ame
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 XenoTech announces an ... cost-effective metabolite production from bioactive small molecules. ... the technology enables convenient and timely assessment of ... XenoTech’s Vice President of Commercial Operations, Christian Darabant, ... clinical risk can be measured directly by comparison ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014 BioElectronics Corporation (OTC Pink: ... devices said that its EVP Dr. ... as part of its Executive Interview Series. ... at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel In ... the unique advantages of BioElectronics patented technology ...
(Date:8/18/2014)... DALLAS , August 18, 2014 ... "Membrane Bioreactor Systems Market, By Application (Municipal Wastewater ... Fiber, Flat Sheet and Multi Tubular), By Configuration ... to 2019", published by MarketsandMarkets, The market for ... million by 2019, growing at a CAGR of ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... is First Entry to Home-Based Device Market Featuring Diode Laser ... ... SpectraGenics, a leader in,light-based therapeutic beauty devices, today announced ... (FDA),for their patented hand-held laser hair removal device designed for ...
... Live on Company,s Website -, TUSTIN, Calif., Feb. ... clinical stage biopharmaceutical,company developing monoclonal antibodies for the treatment ... senior management will,present at the 10th Annual BIO CEO ... am EST. The conference will be held at the,Waldorf-Astoria ...
... or "the Company") (OTC: BPYT) today announced that sales,for ... sales for the month,of January 2007., "We achieved ... continued success of our Flight Spray product. We are ... all-natural solution for,baby care marketed under the Gentle Mother(TM) ...
Cached Biology Technology:TRIA At-Home Laser Hair Removal Device Cleared by FDA 2Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference 2Bioponic Phytoceuticals Announces Record Sales Increase of 40% for the Month of January 2
(Date:8/19/2014)... abstinence syndrome (NAS) secondary to in-utero opioid exposure ... than others, but the underlying reasons are not ... are turned on or off) changes have recently ... University School of Medicine (BUSM) and Boston Medical ... study to identify some of these epigenetic changes ...
(Date:8/19/2014)... other science courses are increasingly being asked to ... have a new textbook to help them do ... month by Princeton Press and co-authored by scientists ... Synthesis (NIMBioS), teaches readers about basic mathematical and ... and explain biological phenomena. , Suitable for entry-level ...
(Date:8/19/2014)... team of UTSA researchers has been awarded a nearly ... and Training (NCPTT), an office of the National Park ... grant will fund a one-year study of the energy ... historic homes in hot, humid climates. , Radiant barriers ... attics that reflect heat back, thereby reducing the amount ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Submissions Leadership Strengthened with Clinical ... and Standards-Based Data Management, WHIPPANY, N.J. and ... today it agreed to terms to acquire Zurich,Biostatistics, ... to,standards-based regulatory submissions, the acquisition further strengthens,ISI,s Clinical ...
... Conference Embarks on New Strategic Direction in 21st Year of ... Embraces Both Flash and HDD Suppliers Under One Roof, ... and its robust dynamic supply chain, IDEMA today announced program,highlights ... be,held on September 18 - 20 at the Hyatt Regency ...
... Leading Healthcare Conference, SUNNYVALE, Calif. and ... a busy healthcare setting is a hectic ... be repeated with each patient,s visit.,Fujitsu Computer ... of,innovative computer products, and HT Systems, a ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3IDEMA Reveals Program Highlights for DISKCON USA 2007 2IDEMA Reveals Program Highlights for DISKCON USA 2007 3IDEMA Reveals Program Highlights for DISKCON USA 2007 4Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4
HybriWell seals securely to a microscope slide surface in seconds to enclose single or multiple specimens in a small reagent volume and eliminate evaporation....
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... the Easy-Titer Human IgM Assay Kit to ... and easy-to-perform assay for Human IgM that ... kit incorporates a simple mix-and-read assay that ... from 15-500 ng/ml in approximately 30 minutes. ...
AC input: 230 V...
Biology Products: